LYUMJEV is a brand name for insulin lispro-aabc, a rapid-acting human insulin analog used to improve glycemic control in adults and children with diabetes mellitus. It is designed to act more quickly than regular human insulin, allowing for closer mimicry of the body's natural insulin response to meals. LYUMJEV works by facilitating the absorption of glucose from the bloodstream into muscle and fat cells, effectively lowering blood sugar levels. It is typically administered via injection shortly before meals to manage the rise in blood glucose that occurs after eating. As with any insulin therapy, the dosing of LYUMJEV must be individualized based on the patient's needs and monitored with regular blood sugar checks to avoid hypoglycemia or other potential side effects.